Indication
Malignant Neoplastic Disease
5 clinical trials
9 products
Clinical trial
A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
TNO155Clinical trial
A Phase 1/2 Trial of Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C MutationStatus: Recruiting, Estimated PCD: 2025-12-31
Product
nab-SirolimusProduct
MRTX849Product
AdagrasibClinical trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1Status: Recruiting, Estimated PCD: 2025-07-01
Product
CetuximabProduct
PembrolizumabProduct
AfatinibProduct
Avutometinib + AdagrasibClinical trial
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)Status: Recruiting, Estimated PCD: 2024-07-24
Product
BI 1701963Clinical trial
A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C MutationStatus: Completed, Estimated PCD: 2022-11-02